Solazyme, Gevo, Amyris Earnings, Outlook: the 5-Minute Version
by Jim Lane (Biofuels Digest) As Solazyme, Gevo and Amyris report on results for Q2, update forward guidance – what does the data reveal about demand, supply of advanced biofuels and co-products? We digest down analyst reports, company comments into a 5-minute summary of “news you can use”.
…Cash, production quantity, offtake and price/margin – these have happily become the new metrics, instead of government R&D contracts, VC financings, and MOUs for future developments.
General themes: as expected, early markets remain focused on higher-value opportunities, fuels (road, aviation or other) are an aspirational goal awaiting the construction of larger capacities and the lower per-gallon costs and assurance of supply that comes with maturity and scale. Analyssts are in general agreement on AMyris; Gevo, all are generally bullish, some more so than others; with Solazyme, Piper Jaffray is somewhat pessimistic but overall the consensus is broadly quite positive. READ MORE
